239 related articles for article (PubMed ID: 24145649)
21. Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells.
Mulligan AM; Plotkin A; Rouzbahman M; Soslow RA; Gilks CB; Clarke BA
Am J Surg Pathol; 2010 Aug; 34(8):1132-8. PubMed ID: 20588176
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
[TBL] [Abstract][Full Text] [Related]
23. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
24. The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes.
Lu L; Wang S; Zhu Q; Qu Y; Gu W; Ning Y; Chen X; Wang Y
Pathol Res Pract; 2018 Aug; 214(8):1087-1094. PubMed ID: 29866423
[TBL] [Abstract][Full Text] [Related]
25. Napsin-A Expression, a Reliable Immunohistochemical Marker for Diagnosis of Ovarian and Endometrial Clear Cell Carcinomas.
Nili F; Tavakoli M; Izadi Mood N; Saffar H; Sarmadi S
Iran J Pathol; 2020; 15(2):81-85. PubMed ID: 32215023
[TBL] [Abstract][Full Text] [Related]
26. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
[TBL] [Abstract][Full Text] [Related]
27. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
28. Napsin-A, a Possible Diagnostic Marker for Differentiating Clear Cell Ovarian Carcinoma From Other High-grade Ovarian Carcinomas.
Alshenawy HA; Radi DA
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):605-610. PubMed ID: 28362708
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma.
Fadare O; Liang SX
Appl Immunohistochem Mol Morphol; 2012 Dec; 20(6):580-7. PubMed ID: 22495362
[TBL] [Abstract][Full Text] [Related]
30. Targeted mutation analysis of endometrial clear cell carcinoma.
Hoang LN; McConechy MK; Meng B; McIntyre JB; Ewanowich C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2015 Apr; 66(5):664-74. PubMed ID: 25308272
[TBL] [Abstract][Full Text] [Related]
31. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features.
Bartosch C; Manuel Lopes J; Oliva E
Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268
[TBL] [Abstract][Full Text] [Related]
32. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.
Mukhopadhyay S; Katzenstein AL
Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283
[TBL] [Abstract][Full Text] [Related]
33. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
Han G; Gilks CB; Leung S; Ewanowich CA; Irving JA; Longacre TA; Soslow RA
Am J Surg Pathol; 2008 Jul; 32(7):955-64. PubMed ID: 18460981
[TBL] [Abstract][Full Text] [Related]
34. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
[TBL] [Abstract][Full Text] [Related]
35. Napsin A is a useful marker for metastatic adenocarcinomas of pulmonary origin.
Kim MY; Go H; Koh J; Lee K; Min HS; Kim MA; Jeon YK; Lee HS; Moon KC; Park SY; Kim WH; Chung DH
Histopathology; 2014 Aug; 65(2):195-206. PubMed ID: 24479710
[TBL] [Abstract][Full Text] [Related]
36. Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissues.
Brustmann H
Pathol Res Pract; 2007; 203(2):65-72. PubMed ID: 17258405
[TBL] [Abstract][Full Text] [Related]
37. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
39. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases.
DeLair D; Oliva E; Köbel M; Macias A; Gilks CB; Soslow RA
Am J Surg Pathol; 2011 Jan; 35(1):36-44. PubMed ID: 21164285
[TBL] [Abstract][Full Text] [Related]
40. The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas.
El-Maqsoud NM; Tawfiek ER; Abdelmeged A; Rahman MF; Moustafa AA
Tumour Biol; 2016 Mar; 37(3):3123-34. PubMed ID: 26427663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
